… Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa (FXa) inhibitor being … population
models for the pharmacokinetics (PK) and pharmacodynamics (PD) ofrivaroxaban in healthy …

… The population pharmacokinetics and pharmacodynamics of rivaroxaban in healthy subjects
… [15] The aim of this analysis was to define the pharmacokinetics and pharmacodynamics of …

… healthy subjects and in the target patient populations, … oral, direct Factor Xa inhibitor
rivaroxaban has a fast onset of action, well-established pharmacokinetics and pharmacodynamics …

… In healthy subjects, maximum inhibition of Factor Xa activity … Population pharmacokinetics
and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients …

… added to plasma from healthy subjects in the concentration range 0… Population
pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in …

…  ) is an oral, direct factor Xa inhibitor in advanced clinical … I study in otherwise healthy
subjects: renal impairment delayed … pharmacology and tolerability of rivaroxaban – an oral, direct …

… of the population average) to be considered a mild deficiency; cases with … factor Xa. Plasma
concentrations correlated with prothrombin time both in healthy volunteers 82 and in patients …

… oral, direct Factor Xa inhibitor rivaroxaban, comparing it with the indirect Factor Xa inhibitor
(fondaparinux), other direct Factor Xa … or AT activity in healthy subjects, demonstrating that …

… its known PK and PD characteristics in healthy subjects and patient populations, and to give
… oral, direct Factor Xa inhibitor to be developed, was designed to specifically target Factor Xa …

… in patients with acute coronary syndromes, a patient population … way crossover study (with
healthy male subjects), antiplatelet … study of 50 healthy subjects), rivaroxaban did not affect …